Abstract: The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting molecule linked to a chelating agent; and a stabilizer against radiolytic degradation comprising ascorbic acid and/or a salt thereof; wherein the composition does not comprise gentisic acid or a salt thereof. The pharmaceutical composition of the present invention provides high stability against radiolytic degradation. The present invention also provides a process for preparing such a pharmaceutical composition.

Abstract: The present invention provides a pharmaceutical composition comprising a radiolabeled complex comprising a radionuclide and a targeting molecule linked to a chelating agent; and a stabilizer against radiolytic degradation comprising ascorbic acid and/or a salt thereof: wherein the composition does not comprise gentisic acid or a salt thereof. The pharmaceutical composition of the present invention provides high stability against radiolytic degradation. The present invention also provides a process for preparing such a pharmaceutical composition.

Abstract: A tool arrangement is provided for accommodating portions of an optical tool in a park position, having an optical tool and having a housing with an opening suitable for accommodating portions of the optical tool in a housing interior, with a housing discharge connected to the housing in a fluid-conducting manner, and with a sealing sleeve arranged at the opening of the housing, wherein the sealing sleeve has a fluid-carrying line for adapting a variable fill volume of the sealing sleeve. In addition, a method is provided for accommodating portions of an optical tool in a park position.

Abstract: A tool arrangement is provided for accommodating portions of an optical tool in a park position, having an optical tool and having a housing with an opening suitable for accommodating portions of the optical tool in a housing interior, with a housing discharge connected to the housing in a fluid-conducting manner, and with a sealing sleeve arranged at the opening of the housing, wherein the sealing sleeve has a fluid-carrying line for adapting a variable fill volume of the sealing sleeve. In addition, a method is provided for accommodating portions of an optical tool in a park position.

Abstract: The present invention relates to a column chromatographic method of manufacturing non-carrier-added high-purity 177Lu compounds for medicinal purposes. In the method in accordance with the invention a cation exchanger and a suitable chelating agent are used. With the method in accordance with the invention it is possible for the first time to provide non-carrier-added high-purity 177Lu compounds in milligram amounts for pharmaceutical-medicinal purposes from 176Yb compounds irradiated with thermal neutrons, the radionuclides 177Lu and 176Yb being present in an approximate mass ratio of 1:102 to 1:1010 for purification.

Abstract: The present invention relates to a carrier system for micro-optical and/or other functional elements of microtechnology, including a base plate and one or more retaining elements for the functional elements that are secured on the base plate. The suggested carrier system is characterized by the fact that the retaining elements are constructed partly or entirely from multiple thin, stacked plates that have a plate thickness of less than 1 mm. In this way, retaining elements for example made from glass or glass ceramic may be created extremely precisely in practically any geometrical shape.

Abstract: The present invention relates to a column chromatographic method of manufacturing non-carrier-added high-purity 177Lu compounds for medicinal purposes. In the method in accordance with the invention a cation exchanger and a suitable chelating agent are used. With the method in accordance with the invention it is possible for the first time to provide non-carrier-added high-purity 177Lu compounds in milligram amounts for pharmaceutical-medicinal purposes from 176Yb compounds irradiated with thermal neutrons, the radionuclides 177Lu and 176Yb being present in an approximate mass ratio of 1:102 to 1:1010 for purification.